Datum Källa Rubrik Typ Alternativ
2023-06-01 Iconovo Iconovo provides increased opportunities for customers in its Novel Pharmaceuticals business segment to finance innovative development projects Pressreleaser Ladda ner | Visa Stäng
2023-06-01 Iconovo Iconovo ökar möjligheterna för kunder inom affärsområdet originalläkemedel att finansiera innovativa utvecklingsprojekt Pressreleaser Ladda ner | Visa Stäng
2023-05-26 Iconovo Kommuniké från årsstämma i Iconovo AB den 22 maj 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-26 Iconovo BioStock: Iconovo initiates structured sales process for ICOpre Pressreleaser Visa Stäng
2023-05-26 Iconovo BioStock: Iconovo inleder strukturerad säljprocess för ICOpre Pressreleaser Visa Stäng
2023-05-23 Iconovo Carl Lindgren new board member of Iconovo Pressreleaser Ladda ner | Visa Stäng
2023-05-23 Iconovo Carl Lindgren ny styrelseledamot i Iconovo Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Iconovo Iconovo initiates structured process for out-licensing of ICOpre with a global investment bank Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Iconovo Iconovo inleder strukturerad process för utlicensiering av ICOpre i samarbete med global investmentbank Pressreleaser Ladda ner | Visa Stäng
2023-05-15 Iconovo BioStock: Iconovo's oxytocin treatment in clinical phase I study Pressreleaser Visa Stäng
2023-05-15 Iconovo BioStock: Iconovos oxytocinbehandling i klinisk fas I-studie Pressreleaser Visa Stäng
2023-05-11 Iconovo Iconovo’s partner Monash University has initiated a phase I clinical trial on inhaled oxytocin in ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-05-11 Iconovo Iconovos partner, Monash University har inlett en klinisk fas I-studie av inhalerat oxytocin i ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-05-02 Penser Access Penser Access: Avtal för ICOone - Iconovo Pressreleaser Visa Stäng
2023-05-02 Penser Access Penser Access: Intervju med Iconovo - Erik Penser Bank - 2 maj 2023 Pressreleaser Visa Stäng
2023-04-28 Iconovo Rättelse: DELÅRSRAPPORT JANUARI - MARS 2023 Rapporter Ladda ner | Visa Stäng
2023-04-28 Iconovo Genomförd riktad emission på 55 MSEK stärker bolaget Rapporter Ladda ner | Visa Stäng
2023-04-28 Iconovo ICONOVO AB PUBLICERAR ÅRSREDOVISNING FÖR 2022 Rapporter Ladda ner | Visa Stäng
2023-04-20 Iconovo Kallelse till årsstämma i Iconovo AB Pressreleaser Ladda ner | Visa Stäng
2023-04-14 Iconovo Iconovo receives new patent in Japan for its ICOone® inhaler platform Pressreleaser Ladda ner | Visa Stäng
2023-04-14 Iconovo Iconovo erhåller nytt patent i Japan för sin inhalatorplattform ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-04-04 Iconovo BioStock: Arcede Pharma och Iconovo erhåller finansiering från Swelife Pressreleaser Visa Stäng
2023-04-04 Iconovo BioStock: Arcede Pharma and Iconovo receive funding from Swelife Pressreleaser Visa Stäng
2023-04-04 Iconovo Iconovo to evaluate ICOone Nasal for the development of antiviral nasal inhalation product Pressreleaser Ladda ner | Visa Stäng
2023-04-04 Iconovo Iconovo utvärderar ICOone Nasal för utveckling av antiviral nasal inhalationsprodukt Pressreleaser Ladda ner | Visa Stäng
2023-03-31 Iconovo Iconovo, Arcede Pharma AB och Lunds universitet erhåller finansiering från Swelife för utveckling av en ny behandling mot KOL och svår astma Pressreleaser Ladda ner | Visa Stäng
2023-03-16 Iconovo Iconovo Pharma har beviljats partihandelstillstånd av Läkemedelsverket Pressreleaser Ladda ner | Visa Stäng
2023-02-15 Penser Access Penser Access: Inhalationsplattformarna klara - Iconovo Pressreleaser Visa Stäng
2023-02-14 Iconovo BioStock: Iconovo carries out directed share issue for continued value creation Pressreleaser Visa Stäng
2023-02-14 Iconovo BioStock: Iconovo genomför riktad emission för fortsatt värdeskapande Pressreleaser Visa Stäng
2023-02-10 Iconovo Iconovos vd förvärvar aktier för 500 000 SEK Pressreleaser Ladda ner | Visa Stäng
2023-02-09 Iconovo Iconovos styrelseledamot och största ägare förvärvar aktier för 3 000 000 SEK Pressreleaser Ladda ner | Visa Stäng
2023-02-08 Iconovo Iconovo AB has completed a directed new share issue of SEK 55 million Pressreleaser Ladda ner | Visa Stäng
2023-02-08 Iconovo Iconovo AB har genomfört en riktad nyemission om 55 miljoner SEK Pressreleaser Ladda ner | Visa Stäng
2023-02-08 Iconovo BOKSLUTSKOMMUNIKÉ 1 JANUARI – 31 DECEMBER 2022 Pressreleaser Ladda ner | Visa Stäng
2023-02-08 Iconovo YEAR-END REPORT JANUARY-DECEMBER 2022 Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 8 Feb 2023 | Iconovo

YEAR-END REPORT JANUARY-DECEMBER 2022

Global interest in Iconovo’s proprietary inhaler platform ICOpre® – ready to address the world’s largest products for Asthma and COPD

Significant events during October 1 – December 31
•Iconovo has started negotiations with a fast-growing generics company regarding Iconovo’s inhaler ICOpre®. The company is part of a global corporate group focused on complex generic products and has an expected turnover of approximately USD 500 – 1,000 million in 2022. The purpose of the negotiations is to enter a license agreement for developing and marketing one or more pharmaceutical products based on Iconovo’s proprietary pre-filled inhaler ICOpre®.

•A second ICOone patent has been approved in Europe. It is an important protection of the solution that allows it to be manufactured as a single component.

•Iconovo has successfully completed a study to map how easy it is to use its inhaler ICOone Nasal. The aim is to make ICOone Nasal so easy to use that anyone can handle it properly without detailed instructions.

•Iconovo has delivered an interim report halfway into the Bill & Melinda Gates project. Good results show that even early in the project, it can be established that a large part of the dose, which is inhaled via the nose, also reaches the lungs.

Signficiant events during January 1 – September 30
•Iconovo announced the completion of a clinical pharmacokinetic pilot study conducted by Amneal Pharmaceuticals. The study has provided valuable information that continues to support the development of ICOres budesonide/formoterol as a potential replacement product for Symbicort. The patent for Symbicort has expired and a stable global market of USD 3.3 billion has been established. The market in Europe has a turnover of approximately USD 1.0 billion.

•Iconovo received an acquisition order from the immunotherapy company Immune System Regulation AB (ISR), which takes the development of an inhalable vaccine against covid-19 closer to a first clinical study. The order meant that the contractual value of the collaboration increased by close to SEK 13.6 million. Iconovo is also entitled to low single-digit royalties on sales of the finished product. ISR has received permission to start a phase I/II clinical study in Bangladesh.

•Iconovo began a strategic collaboration with Galenica AB. The collaboration primarily aims to facilitate the production of clinical trial material for companies developing new medicines using Iconovo’s innovative disposable inhaler ICOone.

•Iconovo updated its long-term financial goals, seeingstrong revenue growth with a high margin. In 2027, Iconovo expects to achieve sales of SEK 250 million. The target for the operating profit for the same year is SEK 125 million, corresponding to an operating margin of 50 percent. About a third of the turnover is estimated to come from Iconovo’s own pharmaceutical sales in the Nordics through the subsidiary Iconovo Pharma.

•The Japanese patent authority issued a notice of allowance regarding Iconovo’s patent application for the inhaler platform ICOone. Iconovo already has a well-established patent portfolio for ICOone in Sweden, Europe (EPO), China, and India.

•The European Patent Office issued a prior approval (Notice of Allowance) regarding Iconovo’s patent application for the inhaler platform ICOres. ICOres is used in several of Iconovo’s customer projects and additional patents extend the period of patent protection to benefit the customers who will launch in the future.

•Iconovo received a grant of SEK 9 million from the Bill & Melinda Gates Foundation to develop inhaled therapies based on ICOone Nasal ahead of the next pandemic. The grant is used to develop a low-cost product that enables the administration of medicinal substances to both the upper and lower respiratory tract. The project will be implemented during the period from August 2022 to June 2023. The aim is to establish a fast track for inhalation treatments that can improve global healthcare, especially in low- and middle-income countries, in the event of a new virus pandemic.

Significant events after the end of the fourth quarter
No significant event occurred after the end of the quarter.

 

Consolidated key figures in TSEK unless otherwise indicated  Oct-Dec 2022 Oct-Dec 2021* Jan-Dec 2022 Jan-Dec 2021*
Net turnover 34 3 600 17 116 15 409
Operating profit/loss -16 588 -8 706 -48 359 -26 513
Cash flow for the period -28 698 -11 960 -81 591 33 348
Earnings per share (SEK) before and after full dilution  
-1,88
 
-0,98
 
-5,44
 
-3,15
Cash and cash equivalents 13 446 95 037 13 446 95 037
Equity 89 294 137 034 89 294 137 034
Number of shares at period end 8 847 500 8 847 500 8 847 500 8 847 500
Number of royalty agreements** 6 6 6 6
Number of feasibility agreements** 1 1 1 2

* Equal to parent company figures as no subsidiaries existed at the time.
**Number of agreements at the end of the period.

CEO COMMENTS

Strong interest from global pharmaceutical companies in Iconovo’s inhaler platforms

We are experiencing strong interest in our inhalation platforms and development expertise from pharmaceutical companies around the world. We have already established collaborations with several companies and shortly after the end of the fourth quarter, we were able to announce that intensive discussions are now underway with a fast-growing generics company, with the aim of signing a licensing agreement for ICOpre in the first half of 2023.
ICOpre offers the same features as GSK’s well-known Ellipta inhaler but is based on our own proprietary technology. Our intention is to develop generic versions of all five products in GSK’s Ellipta portfolio (Relvar/Breo, Anoro, Trelegy, Incruse and Arnuity) which together generated sales of USD 4.2 billion during 2021. In 2025, the first patent for Breo will expire in the US and Iconovo is well-positioned to take advantage of this business opportunity through ICOpre.
 
Continued progress in Gates-funded project
The COVID-19 pandemic has demonstrated the importance of making medicines and vaccines against respiratory infections available quickly and globally. With strong support from the Bill & Melinda Gates Foundation, we are therefore developing a low-cost product based on the ICOone Nasal to enable the administration of medical substances to both the upper and lower respiratory tract. The project has now reached the halfway point and during this time we have built a test station to measure the deposition of drugs in the nose and lungs. The test station includes a 3D cast of the nasal cavity among other things. The results and knowledge from these studies are used to develop our own powder formulation, optimized for simultaneous delivery to the nose and lung, in ICOone Nasal. We can already see that ICOone provides a good distribution of drugs to the nasal cavity, respiratory tract, and lungs. Approximately 50% of the received dose passes down to the lung, which can be considered a very positive result. We can now further optimize the inhaler for different powders to reach the highest possible proportion to the lung. The results so far indicate good prospects for further development towards the goal and establishing a manufacturing process that meets international quality requirements (GMP).
 
New study confirms ease of use of ICOone Nasal
One of the most important features of a good inhaler is its ease of use. If the inhaler is complicated to use, there is a risk of poor adherence to treatment and poor absorption of the drug substance into the body, resulting in reduced efficacy.
 
In October, we were able to present positive results from a user study of ICOone Nasal, showing that our inhaler is appreciated, easy to use, and has an appealing design. The study results confirm the functionality of the ICOone Nasal inhaler and therefore represent an important step forward in the development of the product. Iconovo can now offer its customers additional documentation on the ICOone Nasal inhaler and the received feedback will be valuable for future commercialization. In December we could announce that the USPTO has approved another patent for the ICOone Nasal inhaler, and at the time of writing another patent has been approved in the EU, underlining the innovative nature of the product, and strengthening the protection of exclusivity for future launches.
 
Recruitment process of new CFO successfully completed
We are delighted that Henrik Damkjær Simonsen has accepted the role as our new CFO. He comes from a position as Finance Director at SAGA Diagnostics AB and has previously worked  as CFO at Nuevolution AB and as Head of Life Science, Corporate Finance at SEB. His extensive experience in the life science industry and capital markets is an excellent fit as we work to establish Iconovo as a global leader in inhalation. Henrik will take up his new position on April 1, succeeding Peter Åkerlund, who has been acting CFO since November 16 of last year.
 
From high expenditures to a normal situation in 2023
The development of the ICOpre inhaler has resulted in high development costs, especially in the last half of 2022. The items raw materials and supplies and other external costs have been high, driven by project-related purchases and consultancy costs. As the work on ICOpre has reached the stage where the project is ready to be contracted, our costs will normalize.
 
Solid foundation for continued value creation in 2023
With our unique inhaler platforms, a growing number of commercial partnerships, and a strong team with extensive experience in product development, commercialization, and company building, we are well-positioned to continue creating shareholder value in 2023. There is no doubt that our customer offering is becoming increasingly attractive to pharmaceutical companies worldwide. With Iconovo’s help, they can take advantage of the opportunities offered by modern, patent-protected inhalers, both in the development of new original medicines and in the patent expiries of today’s best-selling inhalation treatments.
 
 
Lund, February 8, 2023
 
Johan Wäborg 
CEO

2023-02-08 Iconovo Iconovo AB evaluates the conditions to carry out a directed new share issue of approximately SEK 50 million and brings forward publication of the year-end report for the financial year 2022 Pressreleaser Ladda ner | Visa Stäng
2023-02-08 Iconovo Iconovo AB utreder förutsättningarna för att genomföra en riktad nyemission om cirka 50 miljoner SEK och tidigarelägger offentliggörande av bokslutskommunikén avseende räkenskapsåret 2022 Pressreleaser Ladda ner | Visa Stäng
2023-02-03 Iconovo Iconovo meddelar positiva resultat i interimsrapport från projekt med ICOone Nasal® Analyser Ladda ner | Visa Stäng
2023-02-03 Iconovo Iconovo announces positive results in interim report from project with ICOone Nasal® Analyser Ladda ner | Visa Stäng
2023-01-26 Iconovo Iconovo erhåller nytt europeiskt patent för sin engångsinhalator ICOone Analyser Ladda ner | Visa Stäng
2023-01-26 Iconovo Iconovo receives approval of new European patent for its single-use inhaler ICOone® Analyser Ladda ner | Visa Stäng
2023-01-17 Iconovo BioStock: Iconovo starts 2023 with negotiations for ICOpre Pressreleaser Visa Stäng
2023-01-17 Iconovo BioStock: Iconovo inleder 2023 med förhandlingar för ICOpre Pressreleaser Visa Stäng
2023-01-11 Iconovo Iconovo har inlett förhandlingar med ett globalt läkemedelsföretag om ett potentiellt licensavtal för sin inhalator ICOpre® Analyser Ladda ner | Visa Stäng
2022-12-15 Iconovo Iconovo utser Henrik Damkjær Simonsen till Chief Financial Officer Analyser Ladda ner | Visa Stäng
2022-12-15 Iconovo Iconovo appoints Henrik Damkjær Simonsen as Chief Financial Officer Analyser Ladda ner | Visa Stäng
2022-12-07 Iconovo Iconovo's ICOone® inhaler platform receives new patent approval in the US Analyser Ladda ner | Visa Stäng
2022-12-07 Iconovo Iconovos inhalatorplattform ICOone® erhåller nytt patentgodkännande i USA Analyser Ladda ner | Visa Stäng
2022-12-05 Iconovo BioStock: Iconovo satsar på läkemedelsförsäljning i Norden Pressreleaser Visa Stäng
2022-12-05 Iconovo BioStock: Iconovo establishes Nordic pharmaceutical sales Pressreleaser Visa Stäng
2022-11-16 Iconovo Iconovo utser Peter Åkerlund till tillförordnad CFO Analyser Ladda ner | Visa Stäng
2022-11-08 Iconovo Valberedning utsedd Iconovo Analyser Ladda ner | Visa Stäng
2022-11-08 Iconovo Nomination Committee appointed at Iconovo Analyser Ladda ner | Visa Stäng
2022-11-08 Iconovo BioStock: Iconovo reports Q3 and arranges pandemic event Pressreleaser Visa Stäng
2022-11-08 Iconovo BioStock: Iconovo rapporterar Q3 och arrangerar pandemievent Pressreleaser Visa Stäng
2022-11-04 Penser Access Penser Access: Intervju med Iconovo - Erik Penser Bank - 3 nov 2022 Analyser Visa Stäng
2022-11-03 Iconovo Abbreviated interim report 1 January - 30 September Analyser Ladda ner | Visa Stäng
2022-10-31 Penser Access Penser Access: Leverans av nya avtal på väg - Iconovo Analyser Visa Stäng
2022-10-28 Iconovo DELÅRSRAPPORT 1 JANUARI – 30 SEPTEMBER 2022 Analyser Ladda ner | Visa Stäng
2022-10-24 Iconovo BioStock: Founder and CTO on Iconovo's journey Pressreleaser Visa Stäng
2022-10-24 Iconovo BioStock: Iconovos grundare och CTO om bolagets resa Pressreleaser Visa Stäng
2022-10-24 Iconovo Iconovos unika engångsinhalator ICOone® Nasal erhöll goda omdömen i användarstudie Analyser Ladda ner | Visa Stäng
2022-10-24 Iconovo Iconovo's unique single dose inhaler ICOone® Nasal received high marks in user study Analyser Ladda ner | Visa Stäng
2022-08-12 Iconovo Iconovos Chief Financial Officer kommer att lämna bolaget under fjärde kvartalet 2022 Analyser Ladda ner | Visa Stäng
2022-08-12 Iconovo BioStock: Iconovos vd om anslaget från Bill & Melinda Gates Foundation Pressreleaser Visa Stäng
2022-07-26 Iconovo Iconovo receives USD 883,800 grant from recognized international foundation to develop inhaled therapy with ICOone Nasal for the next pandemic Analyser Ladda ner | Visa Stäng
2022-07-26 Iconovo Iconovo får 9 MSEK i anslag från ansedd internationell stiftelse för att utveckla inhalerade terapier baserade på ICOone Nasal inför nästa pandemi Analyser Ladda ner | Visa Stäng
2022-07-18 Iconovo Abbreviated interim report 1 January - 30 June 2022 Analyser Ladda ner | Visa Stäng
2022-07-15 Penser Access Penser Access: Q2-rapport andas optimism - Iconovo Analyser Visa Stäng
2022-07-15 Iconovo Delårsrapport 1 januari - 30 juni 2022 Analyser Ladda ner | Visa Stäng
2022-06-20 Iconovo BioStock: Iconovo höjer ribban i sina finansiella mål Pressreleaser Visa Stäng
2022-06-16 Penser Access Penser Access: Dags för djup inandning - Iconovo Analyser Visa Stäng
2022-06-13 Iconovo Iconovo får ytterligare patent godkänt för ICOres® i EU Analyser Ladda ner | Visa Stäng
2022-06-13 Iconovo Iconovo receives approval of additional patent for ICOres® in the EU Analyser Ladda ner | Visa Stäng
2022-06-07 Iconovo Iconovo erhåller förhandsgodkännande av sitt första patent för ICOone® i Japan Analyser Ladda ner | Visa Stäng
2022-06-07 Iconovo First patent granted in Japan for Iconovo’s ICOone Analyser Ladda ner | Visa Stäng
2022-06-03 Iconovo Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin Analyser Ladda ner | Visa Stäng

Kommande händelser

14 Jul 2023 | Kvartalsrapport 2023-Q2
27 Oct 2023 | Kvartalsrapport 2023-Q3
29 Feb 2024 | Bokslutskommuniké 2023